Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ADMA Biologics Inc (ADMA : NSDQ)
 
 • Company Description   
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Number of Employees: 685

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.28 Daily Weekly Monthly
20 Day Moving Average: 3,420,204 shares
Shares Outstanding: 238.73 (millions)
Market Capitalization: $4,364.06 (millions)
Beta: 0.43
52 Week High: $25.67
52 Week Low: $10.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.32% -13.29%
12 Week -2.14% -17.90%
Year To Date 6.59% -0.16%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
465 STATE ROUTE 17
-
RAMSEY,NJ 07446
USA
ph: 201-478-5552
fax: 201-478-5553
michelle@argotpartners.com http://www.admabiologics.com
 
 • General Corporate Information   
Officers
Adam S. Grossman - President and Chief Executive Officer
Steven A. Elms - Chairman
Jerrold B. Grossman - Vice Chairman
Brad Tade - Chief Financial Officer
Alison Finger - Director

Peer Information
ADMA Biologics Inc (CORR.)
ADMA Biologics Inc (RSPI)
ADMA Biologics Inc (CGXP)
ADMA Biologics Inc (BGEN)
ADMA Biologics Inc (GTBP)
ADMA Biologics Inc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 000899104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 238.73
Most Recent Split Date: (:1)
Beta: 0.43
Market Capitalization: $4,364.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.61 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 29.97
Trailing 12 Months: 32.64
PEG Ratio: -
Price Ratios
Price/Book: 11.68
Price/Cash Flow: 33.77
Price / Sales: 9.50
EPS Growth
vs. Year Ago Period: 75.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: 40.22%
vs. Previous Quarter: -2.34%
ROE
06/30/25 - -
03/31/25 - 47.16
12/31/24 - 51.67
ROA
06/30/25 - -
03/31/25 - 30.51
12/31/24 - 29.68
Current Ratio
06/30/25 - -
03/31/25 - 6.58
12/31/24 - 5.97
Quick Ratio
06/30/25 - -
03/31/25 - 3.36
12/31/24 - 2.90
Operating Margin
06/30/25 - -
03/31/25 - 29.32
12/31/24 - 27.96
Net Margin
06/30/25 - -
03/31/25 - 45.01
12/31/24 - 46.35
Pre-Tax Margin
06/30/25 - -
03/31/25 - 30.64
12/31/24 - 29.48
Book Value
06/30/25 - -
03/31/25 - 1.57
12/31/24 - 1.48
Inventory Turnover
06/30/25 - -
03/31/25 - 1.26
12/31/24 - 1.18
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.22
12/31/24 - 0.23
Debt-to-Capital
06/30/25 - -
03/31/25 - 17.79
12/31/24 - 18.82
 

Powered by Zacks Investment Research ©